• Quentin A Hill, Richard J Kelly, Chetan Patalappa, Annika M Whittle, Andrew J Scally, Anthony Hughes, A John Ashcroft, and Anita Hill.
• Haematology Department, St James's Institute of Oncology, St James ’s University Hospital, Leeds, UK. quentinhill@nhs.net
• Leuk. Lymphoma. 2012 Feb 1;53(2):282-8.

AbstractImproved survival in patients with hematological malignancy (HM) admitted to the intensive care unit (ICU) has largely been reported in uncontrolled cohorts from single academic institutions. We compared hospital mortality between 147 patients with HM and 147 general medical admissions to five non-specialist ICUs. The proportion of patients surviving to hospital discharge was significantly worse in patients with HM (27% vs. 56%; p < 0.001). Six-month and 1-year survival in patients with HM was 21% and 18%, respectively. HM, greater age, mechanical ventilation (MV) and acute physiology and chronic health evaluation (APACHE) II score were independent predictors of poor outcome. For patients with HM, culture proven infection, age, MV and inotropes were negative predictors. Disease-specific factors including hematological diagnosis, neutropenia, remission status, prior stem cell transplant, time from diagnosis to admission and degree of prior treatment were not predictive. Overall survival of patients with HM was worse than that recently reported from specialist units.

23 keywords...

hide…